Pilot Trial: Osanetant 28 Days for Prostate Adenocarcinoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
The University of Kansas Cancer Center, Westwood Campus, Kansas City, KSProstate AdenocarcinomaOsanetant - Drug
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial will test if a drug can raise testosterone in men with prostate cancer.

Eligible Conditions
  • Prostate Adenocarcinoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 28 days

28 days
To evaluate the effect of Osanetant on FSH levels.
Luteinizing hormone
To evaluate the effect of Osanetant on PSA levels.
Estradiol
Testosterone

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Pilot Trial: Osanetant 28 Days
1 of 1

Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Pilot Trial: Osanetant 28 Days · No Placebo Group · Phase < 1

Pilot Trial: Osanetant 28 Days
Drug
Experimental Group · 1 Intervention: Osanetant · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
407 Previous Clinical Trials
160,153 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 15 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are there any openings left for prospective participants in this experiment?

"This medical study, which was uploaded to clinicaltrials.gov on the 1st of November 2022 and last updated 4 days later, is not presently recruiting participants. Nonetheless, there are 810 other trials actively welcoming applicants at this time." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.